Hims stock crumbled Tuesday after the telehealth platform issued a lackluster outlook for the current three-month period.

Vertex stock skidded Tuesday on a series of first-quarter setbacks that included light sales, slow uptake for two new drugs and a paused messenger RNA study.Shares of Vertex Pharmaceuticals tumbled 10 ...